| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
7-Azaindole does not have a single defined pharmacological target as it is a scaffold compound used in drug discovery. The 7-azaindole core is a privileged structure that can interact with various biological targets including protein kinases, where it can serve as an ATP-binding site mimetic. Compounds containing the 7-azaindole scaffold have been developed as inhibitors of various kinases, including CDK, Aurora, and JAK families. The compound serves as a versatile building block for drug design.
|
|---|---|
| ln Vitro |
In vitro activity of 7-azaindole derivatives has been extensively studied in drug discovery. The azaindole core can form hydrogen bonds with kinase hinge regions, making it a valuable scaffold for kinase inhibitor development. The compound itself is used as a starting material for synthesizing libraries of azaindole-based compounds. These derivatives are evaluated in various in vitro assays including kinase inhibition assays, cell proliferation assays, and binding studies against specific molecular targets.
|
| ln Vivo |
In vivo activity of 7-azaindole derivatives depends on the specific compound synthesized from this scaffold. Various azaindole-based compounds have been evaluated in animal models for anticancer, anti-inflammatory, and other therapeutic applications. The in vivo activity is assessed based on the specific derivative being studied rather than the parent 7-azaindole. Dosing and administration protocols vary depending on the compound and therapeutic indication.
|
| Enzyme Assay |
For non-cellular assays, 7-azaindole is characterized by standard analytical techniques including NMR, HPLC, and mass spectrometry to confirm identity and purity. The compound can be evaluated as a ligand in binding assays or as a substrate in synthetic reactions. Typical protocols involve dissolving the compound in appropriate solvents and analyzing by chromatographic methods. Purity is typically ≥97% to ≥98%. The compound is a solid at room temperature with a melting point typically around 105-108°C.
|
| Cell Assay |
For in vitro cell-based studies, 7-azaindole derivatives are dissolved in DMSO and diluted in cell culture medium to appropriate concentrations. Cells are cultured under standard conditions and treated with the compounds for various time points. Cellular responses are assessed using assays for viability, proliferation, apoptosis, or specific signaling pathway markers. The 7-azaindole scaffold is used to generate libraries of compounds that are screened against various cancer cell lines and other disease-relevant cell models.
|
| Animal Protocol |
For in vivo animal studies, 7-azaindole derivatives are administered via various routes including oral, intravenous, or intraperitoneal injection depending on the compound and therapeutic application. Dosing solutions are prepared using appropriate vehicles. The compounds are evaluated in animal models of cancer, inflammation, and other diseases. Dosing regimens and administration protocols follow approved animal welfare guidelines and institutional protocols.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7-azaindole derivatives depend on the specific substituents and modifications on the scaffold. The parent compound 7-azaindole has a molecular weight of 118.14. The azaindole core typically provides favorable drug-like properties including the ability to form hydrogen bonds and moderate lipophilicity. Storage: keep in a cool, dry place protected from light and moisture. The compound is stable under recommended storage conditions. Purity: typically ≥97% to ≥98%.
|
| Toxicity/Toxicokinetics |
7-Azaindole is generally considered to have low toxicity as a chemical intermediate, but specific toxicological data depend on the derivative being studied. The compound is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD50 values for 7-azaindole have not been extensively reported in the literature.
|
| Additional Infomation |
1H-pyrrolo[2,3-b]pyridine is a pyrrolopyridine.
7-Azaindole (CAS 271-63-6) is a heterocyclic compound also known as 1H-pyrrolo[2,3-b]pyridine. It is an important scaffold in medicinal chemistry serving as a bioisostere for indole. The 7-azaindole core is used in the synthesis of various kinase inhibitors and other pharmaceutical compounds. It forms hydrogen bonds with kinase hinge regions, making it valuable for drug design. No clinical trials or therapeutic approvals exist for the parent compound; it is a research reagent. |
| Molecular Formula |
C7H6N2
|
|---|---|
| Molecular Weight |
118.14
|
| Exact Mass |
118.053
|
| CAS # |
271-63-6
|
| Related CAS # |
25247-73-8
|
| PubChem CID |
9222
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
283.1±40.0 °C at 760 mmHg
|
| Melting Point |
105-107 °C(lit.)
|
| Flash Point |
125.0±27.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.657
|
| LogP |
-0.64
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
103
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1([H])C([H])=C([H])C2C([H])=C([H])C([H])=NC1=2
|
| InChi Key |
MVXVYAKCVDQRLW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H6N2/c1-2-6-3-5-9-7(6)8-4-1/h1-5H,(H,8,9)
|
| Chemical Name |
1H-pyrrolo[2,3-b]pyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (846.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (21.16 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (21.16 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (21.16 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.4645 mL | 42.3227 mL | 84.6453 mL | |
| 5 mM | 1.6929 mL | 8.4645 mL | 16.9291 mL | |
| 10 mM | 0.8465 mL | 4.2323 mL | 8.4645 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
